Findability Sciences, a leading AI and data science company with strong expertise in healthcare applications, has entered into a strategic Memorandum of Understanding (MoU) to strengthen AI-driven innovation in India’s healthcare sector. The agreement, signed in early 2026, brings together Findability’s advanced AI capabilities with institutional research and policy support to fast-track development and deployment of transformative healthcare solutions.

The MoU emphasizes collaborative efforts in several high-impact areas: AI for diagnostics & imaging enhancing accuracy in radiology, pathology, and point-of-care screening Predictive & preventive analytics early risk identification for chronic diseases, readmissions, and outbreaks Clinical decision support & personalized care generating evidence-based recommendations tailored to Indian patient profiles Drug discovery & clinical research acceleration leveraging AI for target identification, trial optimization, and real-world evidence generation Capacity building & knowledge sharing joint training programs, workshops, and hackathons for healthcare professionals and researchers

Findability Sciences will contribute its proprietary AI platform, domain-trained models, and large-scale data engineering expertise, while the partner institution provides clinical validation environments, access to real-world datasets (anonymized and compliant), and regulatory/policy guidance. The collaboration is expected to produce India-specific AI tools that address local disease patterns, resource constraints, and multilingual requirements.

The initiative aligns closely with national programs such as the Ayushman Bharat Digital Mission (ABDM), National Digital Health Blueprint, and the IndiaAI Mission. It also supports the government’s push for public-private partnerships in deep-tech healthcare innovation, with a focus on equitable access in tier-2/3 cities and rural areas.

This MoU marks a significant step in Findability Sciences’ strategy to expand its healthcare footprint in India, moving from consulting services to co-created, scalable AI products with strong clinical and policy backing.